Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes.
Vieira CP, Fortmann SD, Hossain M, Longhini AL, Hammer SS, Asare-Bediako B, Crossman DK, Sielski MS, Adu-Agyeiwaah Y, Dupont M, Floyd JL, Li Calzi S, Lydic T, Welner RS, Blanchard GJ, Busik JV, Grant MB.
Vieira CP, et al. Among authors: hammer ss.
JCI Insight. 2020 Jul 9;5(13):e137230. doi: 10.1172/jci.insight.137230.
JCI Insight. 2020.
PMID: 32641586
Free PMC article.